Evidence map›Paper›PMID 25563633›Full record

ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2015

Agonist Medications for the Treatment of Cocaine Use Disorder.

S Stevens Negus, Jack Henningfield

Abstract readReview
In one paragraph

Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed.

  1. Open-label pilot study of lisdexamfetamine for cocaine use disorder.The American journal of drug and alcohol abuse · 2021
    Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. [Pharmacological reports : PR · 2025
    Article
  11. Article
  12. Article
  13. Effects of naltrexone on amphetamine choice in rhesus monkeys and rats.Experimental and clinical psychopharmacology · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Environmental Uncertainty and Substance Use Disorders: A Behavior Analytic Perspective.Policy insights from the behavioral and brain sciences · 2023
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

S Stevens NegusDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.
Jack Henningfield1] Pinney Associates, Bethesda, MD, USA [2] Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

Medications Development for Stimulant AbuseR01DA026946 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI NEGUS, SIDNEY S · 2009 to 2019
$3.7M
NIDA NIH HHS R01DA026946
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Clinical Trials as TopicCocaineCocaine-Related DisordersDisease ManagementHumansCocaine

Identifiers

PMID25563633
PMCPMC4839506

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.